Hemgenix

Hemgenix, containing the gene therapy active ingredient etranacogene dezaparvovec, is supplied as an intravenous infusion solution. It is a prescription‑only product approved in the European Union for the treatment of hemophilia B in adults. The therapy uses an adeno‑associated virus vector to deliver a functional copy of the factor IX gene to liver cells, enabling endogenous production of clotting factor IX and improving overall hemostasis.

Hemgenix is indicated for adult patients with hemophilia B (factor IX deficiency) to provide sustained endogenous factor IX production.

- Long‑term reduction of bleeding episodes. - Decreased need for regular factor IX replacement infusions. - Potential improvement in joint health and quality of life. - Use in patients who have developed inhibitors to conventional factor IX products. - May be considered when standard prophylaxis is insufficient or not tolerated.

The safety profile of Hemgenix includes both common and serious adverse events observed in clinical studies.

Common: - Transient elevation of liver enzymes (ALT, AST). - Mild flu‑like symptoms such as fever or fatigue. - Injection‑site reactions including redness or discomfort. - Nausea or mild gastrointestinal upset.

Serious: - Immune‑mediated hepatitis or severe liver injury. - Thrombotic microangiopathy. - Anaphylactic or severe allergic reactions. - Development of neutralizing antibodies reducing efficacy.

Before initiating Hemgenix, clinicians should evaluate several precautionary factors to minimize risk.

- Baseline liver function tests and regular monitoring during treatment. - Screening for pre‑existing antibodies to the AAV vector. - Caution in patients with a history of hepatic disease or elevated transaminases. - Avoid use in pregnant or breastfeeding individuals until safety data are available. - Assess for concurrent use of immunosuppressive therapy. - Consider age and overall health status, as therapy is approved for adults only.

Hemgenix may interact with other medications, requiring careful management of concomitant therapies.

Avoid: - Concurrent use of strong immunosuppressants that could diminish vector efficacy. - Co‑administration with other gene‑therapy products targeting the liver.

Use with caution: - Anticoagulants or antiplatelet agents, due to potential changes in bleeding risk. - Hepatotoxic drugs such as certain antibiotics or antifungals. - Live vaccines, because of altered immune response. - Other biologic agents that may affect immune modulation.